Cadonilimab plus chemotherapy shows 72.5% ORR in 51 patients with cervical cancer.
New Cervical Cancer Drug Shrinks Tumors In Early Real World Tests
This prospective observational cohort study enrolled 51 patients with cervical cancer receiving cadonilimab (≥2 cycles) with chemotherapy, w…
A new cervical cancer drug shows promising results in early real-world tests, shrinking tumors for most patients while keeping side effects …
Network meta-analysis of immunotherapy for persistent, recurrent, or metastatic cervical cancer
Do newer immunotherapies help people with advanced cervical cancer live longer?
This systematic review and network meta-analysis of phase III trials synthesized evidence on first-line immunotherapy regimens for persisten…
Newer immunotherapy combinations help people with advanced cervical cancer live longer and shrink tumors better than standard chemotherapy a…
Cadonilimab therapy in cervical cancer associated with new-onset type 1 diabetes and diabetic ketoacidosis in a case report.
A Cancer Drug Triggered Sudden Diabetes in an 81-Year-Old
This systematic review includes a case report of an 81-year-old female with cervical squamous cell carcinoma who developed diabetic ketoacid…
A powerful cancer drug can switch off the body's insulin supply almost overnight, causing sudden, life-threatening diabetes in patients with…
Case report describes multimodal treatment and single-cell sequencing in NF1 patient with Malignant Triton Tumor
What happens when a rare cancer returns? One young woman's story offers a clue.
A case report describes a 23-year-old woman with neurofibromatosis type 1 and Malignant Triton Tumor. After surgical resection and recurrenc…
A 23-year-old woman with a rare chest tumor found disease stabilization after surgery failed, using a mix of chemotherapy, targeted therapy,…